NCT06876675 2025-03-14
LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer
Peking University Third Hospital
Enrolling by invitation
Clinical Trials
6 trialsNCT06690541 2024-11-15
COMLORLA
Peking University Cancer Hospital & Institute
Not yet recruiting
NCT06532149 2024-08-09
EROS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
NCT06410040 2024-05-10
A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis
Sichuan Cancer Hospital and Research Institute
Active not recruiting
NCT06361589 2024-04-12
Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
Sichuan Cancer Hospital and Research Institute
Recruiting
NCT05167500 2023-03-30
LORLAPULM
Fundación GECP
Completed